Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Pharmacological Comparisons Between Cannabidiol and KLS-13019.

Brenneman DE, Petkanas D, Kinney WA.

J Mol Neurosci. 2018 Sep;66(1):121-134. doi: 10.1007/s12031-018-1154-7. Epub 2018 Aug 14.

PMID:
30109468
2.

Pharmacological Effects on Ceroid Lipofuscin and Neuronal Structure in Cln3 ∆ex7/8 Mouse Brain Cultures.

Brenneman DE, Pearce DA, Kovacs A, DeFrees S.

J Mol Neurosci. 2017 Sep;63(1):100-114. doi: 10.1007/s12031-017-0962-5. Epub 2017 Aug 15.

PMID:
28812237
3.

Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.

Kinney WA, McDonnell ME, Zhong HM, Liu C, Yang L, Ling W, Qian T, Chen Y, Cai Z, Petkanas D, Brenneman DE.

ACS Med Chem Lett. 2016 Feb 10;7(4):424-8. doi: 10.1021/acsmedchemlett.6b00009. eCollection 2016 Apr 14.

4.

A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety.

Ross TM, Battista K, Bignan GC, Brenneman DE, Connolly PJ, Liu J, Middleton SA, Orsini M, Reitz AB, Rosenthal DI, Scott MK, Vaidya AH.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):602-6. doi: 10.1016/j.bmcl.2014.12.015. Epub 2014 Dec 17.

PMID:
25556095
5.

Small-molecule anticonvulsant agents with potent in vitro neuroprotection and favorable drug-like properties.

Smith GR, Brenneman DE, Zhang Y, Du Y, Reitz AB.

J Mol Neurosci. 2014 Mar;52(3):446-58. doi: 10.1007/s12031-013-0180-8. Epub 2013 Nov 26.

6.

Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Reitz AB, Maryanoff BE.

J Med Chem. 2013 Nov 27;56(22):9019-30. doi: 10.1021/jm400894u. Epub 2013 Nov 11.

7.

Small molecule anticonvulsant agents with potent in vitro neuroprotection.

Brenneman DE, Smith GR, Zhang Y, Du Y, Kondaveeti SK, Zdilla MJ, Reitz AB.

J Mol Neurosci. 2012 Jun;47(2):368-79. doi: 10.1007/s12031-012-9765-x. Epub 2012 Apr 26.

8.

Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.

Huang Y, Strobel ED, Ho CY, Reynolds CH, Conway KA, Piesvaux JA, Brenneman DE, Yohrling GJ, Moore Arnold H, Rosenthal D, Alexander RS, Tounge BA, Mercken M, Vandermeeren M, Parker MH, Reitz AB, Baxter EW.

Bioorg Med Chem Lett. 2010 May 15;20(10):3158-60. doi: 10.1016/j.bmcl.2010.03.097. Epub 2010 Mar 30.

PMID:
20399652
9.

Cathepsins B and L differentially regulate amyloid precursor protein processing.

Klein DM, Felsenstein KM, Brenneman DE.

J Pharmacol Exp Ther. 2009 Mar;328(3):813-21. doi: 10.1124/jpet.108.147082. Epub 2008 Dec 8.

10.

Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons.

Liu Y, Yohrling GJ, Wang Y, Hutchinson TL, Brenneman DE, Flores CM, Zhao B.

Epilepsy Res. 2009 Jan;83(1):66-72. doi: 10.1016/j.eplepsyres.2008.09.006. Epub 2008 Nov 14.

PMID:
19013768
11.

2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead.

Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL, Reynolds CH, Tounge BA, Luo C, Scott MK, Huang Y, Braeken M, Pieters SM, Berthelot DJ, Masure S, Bruinzeel WD, Jordan AD, Parker MH, Boyd RE, Qu J, Alexander RS, Brenneman DE, Reitz AB.

J Med Chem. 2007 Sep 6;50(18):4261-4. Epub 2007 Aug 8.

PMID:
17685503
12.

Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations.

Malatynska E, Pinhasov A, Crooke JJ, Smith-Swintosky VL, Brenneman DE.

J Neurosci Methods. 2007 Sep 30;165(2):175-82. Epub 2007 Jun 15.

PMID:
17645948
13.

A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta.

Yohrling GJ, Felsenstein KM, Conway KA, Zupa-Fernandez A, Brenneman DE, Arnold HM.

Curr Alzheimer Res. 2007 Jul;4(3):297-303.

PMID:
17627487
14.

Assessing activity onset time and efficacy for clinically effective antidepressant and antimanic drugs in animal models based on dominant-submissive relationships.

Malatynska E, Pinhasov A, Creighton CJ, Crooke JJ, Reitz AB, Brenneman DE, Lubomirski MS.

Neurosci Biobehav Rev. 2007;31(6):904-19. Epub 2007 May 24. Review.

PMID:
17597209
15.
16.

NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis.

Busciglio J, Pelsman A, Helguera P, Ashur-Fabian O, Pinhasov A, Brenneman DE, Gozes I.

Curr Pharm Des. 2007;13(11):1091-8.

PMID:
17430172
18.

Levels of mRNA coding for alpha-, beta-, and gamma-synuclein in the brains of newborn, juvenile, and adult rats.

Malatynska E, Pinhasov A, Crooke J, Horowitz D, Brenneman DE, Ilyin SE.

J Mol Neurosci. 2006;29(3):269-77.

PMID:
17085784
19.

Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.

Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I.

Neuron Glia Biol. 2004 Aug;1(3):193-9.

20.

8-(Heteroaryl)phenalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as opioid receptor modulators.

Jordan AD, Orsini MJ, Middleton SA, Connolly PJ, Brenneman DE, Pan K, Reitz AB.

Med Chem. 2005 Nov;1(6):601-10.

PMID:
16787343
21.

Learning enhancement with neuropeptides.

Toso L, Endres M, Vink J, Abebe DT, Brenneman DE, Spong CY.

Am J Obstet Gynecol. 2006 Apr;194(4):1153-8; discussion 1158-9.

PMID:
16580319
22.

Novel peptides prevent alcohol-induced spatial learning deficits and proinflammatory cytokine release in a mouse model of fetal alcohol syndrome.

Vink J, Auth J, Abebe DT, Brenneman DE, Spong CY.

Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):825-9.

PMID:
16150281
24.

Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.

Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR.

J Mol Neurosci. 2005;25(3):225-38.

PMID:
15800376
25.

Different levels of gamma-synuclein mRNA in the cerebral cortex of dominant, neutral and submissive rats selected in the competition test.

Pinhasov A, Ilyin SE, Crooke J, Amato FA, Vaidya AH, Rosenthal D, Brenneman DE, Malatynska E.

Genes Brain Behav. 2005 Feb;4(1):60-4.

26.

Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus.

Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, Gozes I.

Neurosci Lett. 2005 Jan 3;373(1):73-8.

PMID:
15555780
27.

High-throughput siRNA-based functional target validation.

Xin H, Bernal A, Amato FA, Pinhasov A, Kauffman J, Brenneman DE, Derian CK, Andrade-Gordon P, Plata-Salamán CR, Ilyin SE.

J Biomol Screen. 2004 Jun;9(4):286-93.

PMID:
15191645
28.

Gene expression analysis for high throughput screening applications.

Pinhasov A, Mei J, Amaratunga D, Amato FA, Lu H, Kauffman J, Xin H, Brenneman DE, Johnson DL, Andrade-Gordon P, Ilyin SE.

Comb Chem High Throughput Screen. 2004 Mar;7(2):133-40.

PMID:
15032660
29.

Protective peptides that are orally active and mechanistically nonchiral.

Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I.

J Pharmacol Exp Ther. 2004 Jun;309(3):1190-7. Epub 2004 Mar 8.

30.

The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide.

Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, Gozes I.

Peptides. 2003 Sep;24(9):1413-23.

PMID:
14706557
31.

The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome.

Poggi SH, Goodwin K, Hill JM, Brenneman DE, Tendi E, Schinelli S, Abebe D, Spong CY.

Am J Obstet Gynecol. 2003 Sep;189(3):790-3.

PMID:
14526315
32.

Differential expression of c-fos in a mouse model of fetal alcohol syndrome.

Poggi SH, Goodwin KM, Hill JM, Brenneman DE, Tendi E, Schninelli S, Spong CY.

Am J Obstet Gynecol. 2003 Sep;189(3):786-9.

PMID:
14526314
33.

From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.

Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD.

J Mol Neurosci. 2003;20(3):315-22. Review.

PMID:
14501014
34.

Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome.

Hill JM, Ades AM, McCune SK, Sahir N, Moody EM, Abebe DT, Crnic LS, Brenneman DE.

Exp Neurol. 2003 Sep;183(1):56-65.

PMID:
12957488
35.

Activity-dependent neuroprotective protein: a novel gene essential for brain formation.

Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I.

Brain Res Dev Brain Res. 2003 Aug 12;144(1):83-90.

PMID:
12888219
37.

Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity.

Wilkemeyer MF, Chen SY, Menkari CE, Brenneman DE, Sulik KK, Charness ME.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8543-8. Epub 2003 Jun 13.

38.

Antagonism of VIP-stimulated cyclic AMP formation in chick brain.

Nowak JZ, Sedkowska P, Zawilska JB, Gozes I, Brenneman DE.

J Mol Neurosci. 2003 Apr;20(2):163-72.

PMID:
12794310
39.

Complex array of cytokines released by vasoactive intestinal peptide.

Brenneman DE, Phillips TM, Hauser J, Hill JM, Spong CY, Gozes I.

Neuropeptides. 2003 Apr;37(2):111-9.

PMID:
12747943
40.

Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development.

Poggi SH, Vink J, Goodwin K, Hill JM, Brenneman DE, Pinhasov A, Gozes I, Spong CY.

Am J Obstet Gynecol. 2002 Oct;187(4):973-6.

PMID:
12388989
41.

Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse.

Hill JM, Mehnert J, McCune SK, Brenneman DE.

Peptides. 2002 Oct;23(10):1803-8.

PMID:
12383868
42.

Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity.

Brenneman DE, Hauser JM, Spong C, Phillips TM.

Neuropeptides. 2002 Aug;36(4):271-80.

PMID:
12372701
43.

A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes.

Steingart RA, Heldenberg E, Pinhasov A, Brenneman DE, Fridkin M, Gozes I.

Life Sci. 2002 Oct 11;71(21):2543-52.

PMID:
12270759
44.

The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase.

Wollman Y, Blumberg S, Spungin A, Brenneman DE, Fridkin M, Wollman J, Iaina A, Gozes I.

Regul Pept. 2002 Oct 15;108(2-3):175-7.

PMID:
12220742
45.

Vasoactive intestinal peptide mRNA and immunoreactivity are decreased in fetal alcohol syndrome model.

Spong CY, Auth J, Vink J, Goodwin K, Abebe DT, Hill JM, Brenneman DE.

Regul Pept. 2002 Oct 15;108(2-3):143-7.

PMID:
12220738
46.

NAP accelerates the performance of normal rats in the water maze.

Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):167-70.

PMID:
12212775
47.

NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death.

Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I.

Stroke. 2002 Apr;33(4):1085-92.

PMID:
11935065
48.

A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis.

Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I.

J Mol Neurosci. 2002 Feb-Apr;18(1-2):37-45.

PMID:
11931348
49.

Neuropeptides: brain messengers of many faces.

Gozes I, Brenneman DE, Geppetti P, Kastin AJ, Mains RE, Moody TW, Seroogy K, Spier AD, Zimmermann M.

Trends Neurosci. 2001 Dec;24(12):687-90.

PMID:
11718856
50.

A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.

Gelber E, Granoth R, Fridkin M, Dreznik Z, Brenneman DE, Moody TW, Gozes I.

Cancer. 2001 Oct 15;92(8):2172-80.

PMID:
11596035

Supplemental Content

Loading ...
Support Center